--- title: "Nanjing Leads Biolabs Co. (9887) stock and investor profile" url: "https://aibio.space/companies/nanjing-leads-biolabs/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "Nanjing Leads Biolabs Co., Ltd. (HKEX: 9887), China. The directory classifies it as Biotechnology." --- 9887 Nanjing Leads Biolabs Co., Ltd. HKEX · China # Nanjing Leads Biolabs Co. (9887) news Nanjing Leads Biolabs Co., Ltd. is a public biotech or pharmaceutical company listed on HKEX under the ticker 9887, recorded under China. The directory classifies it as Biotechnology. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. ## Latest Nanjing Leads Biolabs Co. news We have not published a story on Nanjing Leads Biolabs Co. yet. When there is news, it will appear here. ## Nanjing Leads Biolabs Co. at a glance - **Ticker**: 9887 - **Listing**: HKEX - **Country**: China ### Related companies - [Sinocelltech Group](https://aibio.space/companies/sinocelltech/) SSE: 688520 - [Chongqing Zhifei Biological Products Co.](https://aibio.space/companies/chongqing-zhifei-biological-products/) SZSE: 300122 - [Walvax Biotechnology Co.](https://aibio.space/companies/walvax-biotechnology/) SZSE: 300142 - [Qingdao Vland Biotech INC.](https://aibio.space/companies/qingdao-vland-biotech/) SSE: 603739 - [Shaanxi Micot Pharmaceutical Technology Co.](https://aibio.space/companies/shaanxi-micot-pharmaceutical-technology/) HKEX: 2335 - [Hualan Biological Engineering](https://aibio.space/companies/hualan-biological-engineering/) SZSE: 002007 - [Medtide](https://aibio.space/companies/medtide/) HKEX: 3880 - [Liaoning Chengda Biotechnology Co.](https://aibio.space/companies/liaoning-chengda-biotechnology/) SSE: 688739 ### Also on HKEX - [Ascletis Pharma](https://aibio.space/companies/ascletis-pharma/) 1672 - [B&K Corporation](https://aibio.space/companies/b-k/) 2396 - [Ocumension Therapeutics](https://aibio.space/companies/ocumension-therapeutics/) 1477 - [Beijing Biostar Pharmaceuticals Co.](https://aibio.space/companies/beijing-biostar-pharmaceuticals/) 2563 - [Cutia Therapeutics](https://aibio.space/companies/cutia-therapeutics/) 2487 - [Hangzhou Jiuyuan Genetic Biopharmaceutical Co.](https://aibio.space/companies/hangzhou-jiuyuan-genetic-biopharmaceutical/) 2566 ## Questions about Nanjing Leads Biolabs Co. What is the ticker symbol of Nanjing Leads Biolabs Co.? Nanjing Leads Biolabs Co., Ltd. trades under the ticker 9887 on HKEX. Where is Nanjing Leads Biolabs Co. listed? Nanjing Leads Biolabs Co., Ltd. is listed on HKEX. Which country or territory is Nanjing Leads Biolabs Co. listed under? Our directory records Nanjing Leads Biolabs Co., Ltd. under China. What does Nanjing Leads Biolabs Co. do? Our directory classifies Nanjing Leads Biolabs Co., Ltd. as: Biotechnology. This is a directory classification, not a description of the pipeline. What is the ISIN of Nanjing Leads Biolabs Co.? The ISIN recorded for Nanjing Leads Biolabs Co., Ltd. is CNE1000070H8. Does aibio.space cover Nanjing Leads Biolabs Co.? aibio.space lists Nanjing Leads Biolabs Co., Ltd. among 2,820 public biotech companies and publishes its news here as stories appear. Which companies are similar to Nanjing Leads Biolabs Co.? Companies in our directory listed in the same country and business area as Nanjing Leads Biolabs Co.: Sinocelltech Group, Chongqing Zhifei Biological Products Co., Walvax Biotechnology Co., Qingdao Vland Biotech INC., Shaanxi Micot Pharmaceutical Technology Co., Hualan Biological Engineering. ## Investor discussion: Nanjing Leads Biolabs Co. Members talk about Nanjing Leads Biolabs Co. (9887). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Nanjing Leads Biolabs Co., newest first. Each line links the filing it comes from. 1. 2026-04-24 Financings Share or debt issue: (1) 2025 WORK REPORT OF THE BOARD OF DIRECTORS; (2) 2025 FINAL FINANCIAL REPORT; (3) 2025 ANNUAL REPORT; (4) 2025 PROFIT DISTRIBUTION PLAN; (5) PROPOSED APPOINTMENT OF NON-EXECUTIVE DIRECTOR; (6) RE-APPOINTMENT OF AUDITOR; (7) 2026 DIRECTORS REMUNERATION PLAN; (8) GENERAL MANDATE TO ISSUE NEW SHARES; (9) GENERAL MANDATE TO REPURCHASE H SHARES; (10) PROPOSED AMENDMENTS TO THE ARTICLES OF ASSOCIATION; AND NOTICE OF THE ANNUAL GENERAL MEETING. [Source](https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0424/2026042403388.pdf) 2. 2025-07-16 Financings Share or debt issue: GLOBAL OFFERING. [Source](https://www1.hkexnews.hk/listedco/listconews/sehk/2025/0717/2025071700005.pdf) ## Press releases Headlines of Nanjing Leads Biolabs Co.'s own announcements, newest first. Each opens the full release on the newswire that carried it. 1. 2026-10-26 HKEXnews [VOLUNTARY ANNOUNCEMENT PRESENTATION OF UPDATED CLINICAL AND TRANSLATIONAL DATA OF LBL-024 FOR EXTRAPULMONARY NEUROENDOCRINE CARCINOMA, BILIARY TRACT CANCER AND COLORECTAL CANCER AT 2026 ESMO](https://www1.hkexnews.hk/listedco/listconews/sehk/2026/1026/2026102600652.pdf) 2. 2026-10-25 HKEXnews [VOLUNTARY ANNOUNCEMENT ORAL PRESENTATION OF UPDATED CLINICAL DATA OF LBL-034 FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA AT 2026 ESMO](https://www1.hkexnews.hk/listedco/listconews/sehk/2026/1025/2026102500007.pdf) 3. 2026-10-20 HKEXnews [VOLUNTARY ANNOUNCEMENT PHASE II STUDY OF LBL-024 (OPAMTISTOMIG, PD-L1/4-1BB BISPECIFIC ANTIBODY) AS FIRST-LINE TREATMENT FOR GASTRIC CANCER PROGRESSES TO EXPANSION STAGE](https://www1.hkexnews.hk/listedco/listconews/sehk/2026/1020/2026102000577.pdf) 4. 2026-10-19 HKEXnews [VOLUNTARY ANNOUNCEMENT ABSTRACTS OF SIX STUDIES PUBLISHED AT 2026 ESMO](https://www1.hkexnews.hk/listedco/listconews/sehk/2026/1019/2026101900259.pdf) 5. 2026-10-16 HKEXnews [VOLUNTARY ANNOUNCEMENT FIRST PATIENT ENROLLED IN PHASE IB/II CLINICAL TRIAL OF LBL-024 (OPAMTISTOMIG, PD-L1/4-1BB BISPECIFIC ANTIBODY) IN COMBINATION THERAPY FOR METASTATIC COLORECTAL CANCER](https://www1.hkexnews.hk/listedco/listconews/sehk/2026/1016/2026101600215.pdf) 6. 2026-10-11 HKEXnews [VOLUNTARY ANNOUNCEMENT LBL-024 (OPAMTISTOMIG, PD-L1/4-1BB BISPECIFIC ANTIBODY) GRANTED FAST TRACK DESIGNATION BY THE U.S. FDA FOR FIRST-LINE TREATMENT OF ADVANCED BILIARY TRACT CANCER](https://www1.hkexnews.hk/listedco/listconews/sehk/2026/1012/2026101200001.pdf) 7. 2026-09-28 HKEXnews [VOLUNTARY ANNOUNCEMENT LBL-024 (OPAMTISTOMIG, PD-L1/4-1BB BISPECIFIC ANTIBODY) GRANTED ORPHAN DRUG DESIGNATION IN JAPAN](https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0928/2026092800285.pdf) 8. 2026-09-21 HKEXnews [VOLUNTARY ANNOUNCEMENT PIVOTAL REGISTRATIONAL PHASE IIB STUDY OF LBL-024 (OPAMTISTOMIG, PD-L1/4-1BB BISPECIFIC ANTIBODY) MONOTHERAPY IN ADVANCED EP-NEC SELECTED AS LBA AND THREE STUDIES SELECTED FOR PROFFERED PAPER PRESENTATIONS AT 2026 ESMO](https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0921/2026092101756.pdf) 9. 2026-09-14 HKEXnews [VOLUNTARY ANNOUNCEMENT UPDATED DATA FROM PHASE II CLINICAL STUDY OF LBL-024 (OPAMTISTOMIG, PD-L1/4-1BB BISPECIFIC ANTIBODY) IN COMBINATION WITH CHEMOTHERAPY AS FIRST-LINE TREATMENT FOR NSCLC PRESENTED ORALLY AT WCLC 2026](https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0914/2026091400584.pdf) 10. 2026-08-31 HKEXnews [INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED JUNE 30, 2026](https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0831/2026083100538.pdf) 11. 2026-08-24 HKEXnews [VOLUNTARY ANNOUNCEMENT LBL-024 (OPAMTISTOMIG, PD-L1/4-1BB BISPECIFIC ANTIBODY) PHASE II CLINICAL STUDY FOR FIRST-LINE TREATMENT OF ESCC ADVANCES TO EXPANSION STAGE](https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0825/2026082500037.pdf) 12. 2026-08-21 HKEXnews [VOLUNTARY ANNOUNCEMENT LBL-024 (OPAMTISTOMIG, PD-L1/4-1BB BISPECIFIC ANTIBODY) NEW DRUG APPLICATION ACCEPTED FOR REVIEW BY NMPA](https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0821/2026082100348.pdf) 13. 2026-08-20 HKEXnews [VOLUNTARY ANNOUNCEMENT LBL-024 (OPAMTISTOMIG, PD-L1/4-1BB BISPECIFIC ANTIBODY) PHASE II CLINICAL STUDY ABSTRACT FOR FIRST-LINE TREATMENT OF NSCLC PUBLISHED ON WCLC WEBSITE](https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0820/2026082000049.pdf) 14. 2026-08-19 HKEXnews [VOLUNTARY ANNOUNCEMENT OBLENIO EXERCISED OPTION TO RETAIN ITS LICENSE FOR LBL-051](https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0820/2026082000017.pdf) 15. 2026-08-05 HKEXnews [VOLUNTARY ANNOUNCEMENT PHASE II STUDY OF LBL-024 (OPAMTISTOMIG, PD-L1/4-1BB BISPECIFIC ANTIBODY) FOR HEPATOCELLULAR CARCINOMA SUCCESSFULLY ENTERS EXPANSION PHASE](https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0806/2026080600005.pdf) 16. 2026-08-04 HKEXnews [VOLUNTARY ANNOUNCEMENT PARTNER OBLENIO DOSES FIRST PATIENTS IN PHASE IA TRIAL OF LBL-051 FOR REFRACTORY AUTOIMMUNE DISEASES AND SUPPLEMENTAL ANNOUNCEMENT](https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0804/2026080401899.pdf) 17. 2026-08-02 HKEXnews [VOLUNTARY ANNOUNCEMENT LBL-024 (OPAMTISTOMIG, PD-L1/4-1BB BISPECIFIC ANTIBODY) RECEIVED IND APPROVAL FROM NMPA FOR THE TREATMENT OF METASTATIC COLORECTAL CANCER](https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0803/2026080300001.pdf) 18. 2026-07-30 HKEXnews [VOLUNTARY ANNOUNCEMENT - COMPLETION OF FULL PATIENT ENROLLMENT IN PHASE II STUDY OF LBL-024 (OPAMTISTOMIG, PD-L1/4-1BB BISPECIFIC ANTIBODY) FOR BILIARY TRACT CANCER](https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0730/2026073001116.pdf) 19. 2026-07-24 HKEXnews [VOLUNTARY ANNOUNCEMENT VOLUNTARY EXTENSION OF LOCK-UP PERIOD GIVEN BY THE CHIEF EXECUTIVE OFFICER](https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0724/2026072400999.pdf) 20. 2026-07-13 HKEXnews [VOLUNTARY ANNOUNCEMENT MULTIPLE RESEARCH RESULTS SELECTED FOR PRESENTATION AT 2026 ESMO](https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0713/2026071300248.pdf) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open HKEX:9887 on TradingView](https://www.tradingview.com/symbols/HKEX-9887/). ## Listing details Nanjing Leads Biolabs Co., Ltd. is a public biotech or pharmaceutical company listed on HKEX under the ticker 9887, recorded under China. The directory classifies it as Biotechnology. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Nanjing Leads Biolabs Co., Ltd. - **Ticker**: 9887 - **Listing**: HKEX - **Country or territory**: China - **Business scope**: Biotechnology - **ISIN**: CNE1000070H8 - **Last quote in directory**: 2026-10-22 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/HKEX-9887/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/nanjing-leads-biolabs/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Nanjing Leads Biolabs Co. (9887) stock and investor profile", 2026-10-31, https://aibio.space/companies/nanjing-leads-biolabs/